The analysis of uPA/PAI-1 can thus usefully supplement the information gained from conventional clinical-pathological parameters in the decision for or against adjuvant chemotherapy in cases of hormone-receptor-positive, Her2/neu-negative breast carcinomas [27], even before a multigene test has to be arranged. The gene discussed is PLAU; the disease is breast carcinoma.